Literature DB >> 16185266

Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000.

Susan M Swetter1, Jennifer C Boldrick, Sandy Y Jung, Barbara M Egbert, Jeff D Harvell.   

Abstract

Worldwide, lentigo maligna melanoma (LMM) comprises 4%-15% of cutaneous melanoma and occurs less commonly than superficial spreading or nodular subtypes. We assessed the incidence of melanoma subtypes in regional and national Surveillance, Epidemiology, and End Results (SEER) cancer registry data from 1990 to 2000. Because 30%-50% of SEER data were not classified by histogenetic type, we compared the observed SEER trends with an age-matched population of 1024 cases from Stanford University Medical Center (SUMC) (1995-2000). SEER data revealed lentigo maligna (LM) as the most prevalent in situ subtype (79%-83%), and that LMM has been increasing at a higher rate compared with other subtypes and to all invasive melanoma combined for patients aged 45-64 and > or =65 y. The SUMC data demonstrated LM and LMM as the only subtypes increasing in incidence over the study period. In both groups, LM comprised > or =75% of in situ melanoma and LMM > or =27% of invasive melanoma in men 65 y and older. Regional and national SEER data suggest an increasing incidence of LM and LMM, particularly in men > or =age 65. An increased incidence of LM subtypes should direct melanoma screening to heavily sun-exposed sites, where these subtypes predominate.

Entities:  

Mesh:

Year:  2005        PMID: 16185266     DOI: 10.1111/j.0022-202X.2005.23852.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  31 in total

1.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

Review 2.  Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management.

Authors:  Karen L Connolly; Kishwer S Nehal; Klaus J Busam
Journal:  Melanoma Manag       Date:  2015-05-18

3.  University Hospital Waterford: 5-year experience of cutaneous melanoma.

Authors:  R Sehgal; C X Cheung; R Alradadi; D A Healy; R Landers; G T O'Donoghue
Journal:  Ir J Med Sci       Date:  2016-11-21       Impact factor: 1.568

Review 4.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

5.  Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.

Authors:  Adi Nosrati; Jacqueline G Berliner; Shilpa Goel; Joseph McGuire; Vera Morhenn; Juliana R de Souza; Yildiray Yeniay; Rasnik Singh; Kristina Lee; Mio Nakamura; Rachel R Wu; Ann Griffin; Barbara Grimes; Eleni Linos; Mary Margaret Chren; Roy Grekin; Maria L Wei
Journal:  JAMA Dermatol       Date:  2017-05-01       Impact factor: 10.282

6.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Authors:  Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

7.  Melanoma in situ in a private practice setting 2005 through 2009: location, lesion size, lack of concern.

Authors:  Sherea M Stricklin; William V Stoecker; Joseph M Malters; Rhett Drugge; Margaret Oliviero; Harold S Rabinovitz; Lindall A Perry
Journal:  J Am Acad Dermatol       Date:  2012-01-09       Impact factor: 11.527

8.  Gender differences, UV exposure and risk of lentigo maligna in a nationwide healthcare population cohort study.

Authors:  H W Higgins; E Cho; M A Weinstock; T Y Li; A Qureshi; W Q Li
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-12-05       Impact factor: 6.166

Review 9.  Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Authors:  Aljosja Rogiers; Joost J van den Oord; Marjan Garmyn; Marguerite Stas; Cindy Kenis; Hans Wildiers; Jean-Christophe Marine; Pascal Wolter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

10.  Host risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men.

Authors:  Andrew C Walls; Jiali Han; Tricia Li; Abrar A Qureshi
Journal:  Am J Epidemiol       Date:  2013-04-11       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.